Treatment of primary Sjögren syndrome with rituximab: a randomized trial
- PMID: 24727841
- DOI: 10.7326/M13-1085
Treatment of primary Sjögren syndrome with rituximab: a randomized trial
Abstract
Background: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by ocular and oral dryness or systemic manifestations.
Objective: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS.
Design: Randomized, placebo-controlled, parallel-group trial conducted between March 2008 and January 2011. Study personnel (except pharmacists), investigators, and patients were blinded to treatment group. (ClinicalTrials.gov: NCT00740948).
Setting: 14 university hospitals in France.
Patients: 120 patients with scores of 50 mm or greater on at least 2 of 4 visual analogue scales (VASs) (global disease, pain, fatigue, and dryness) and recent-onset (< 10 years) biologically active or systemic pSS.
Intervention: Randomization (1:1 ratio) to rituximab (1 g at weeks 0 and 2) or placebo.
Measurements: Primary end point was improvement of at least 30 mm in 2 of 4 VASs by week 24.
Results: No significant difference between groups in the primary end point was found (difference, 1.0% [95% CI, -16.7% to 18.7%]). The proportion of patients with at least 30-mm decreases in at least two of the four VAS scores was higher in the rituximab group at week 6 (22.4% vs. 9.1%; P = 0.036). An improvement of at least 30 mm in VAS fatigue score was more common with rituximab at weeks 6 (P < 0.001) and 16 (P = 0.012), and improvement in fatigue from baseline to week 24 was greater with rituximab. Adverse events were similar between groups except for a higher rate of infusion reactions with rituximab.
Limitation: Low disease activity at baseline and a primary outcome that may have been insensitive to detect clinically important changes.
Conclusion: Rituximab did not alleviate symptoms or disease activity in patients with pSS at week 24, although it alleviated some symptoms at earlier time points.
Comment in
-
Treatment of primary Sjögren syndrome with rituximab.Ann Intern Med. 2014 Sep 2;161(5):376-7. doi: 10.7326/L14-5017-3. Ann Intern Med. 2014. PMID: 25178574 No abstract available.
-
Treatment of primary Sjögren syndrome with rituximab. In response.Ann Intern Med. 2014 Sep 2;161(5):377-8. doi: 10.7326/L14-5017-4. Ann Intern Med. 2014. PMID: 25178575 No abstract available.
Summary for patients in
-
Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?Ann Intern Med. 2014 Feb 18;160(4):I-11. doi: 10.7326/P14-9005. Ann Intern Med. 2014. PMID: 25006621 No abstract available.
Similar articles
-
Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?Ann Intern Med. 2014 Feb 18;160(4):I-11. doi: 10.7326/P14-9005. Ann Intern Med. 2014. PMID: 25006621 No abstract available.
-
Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.JAMA. 2014 Jul 16;312(3):249-58. doi: 10.1001/jama.2014.7682. JAMA. 2014. PMID: 25027140 Clinical Trial.
-
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.Ann Rheum Dis. 2008 Nov;67(11):1541-4. doi: 10.1136/ard.2007.083865. Epub 2008 Feb 14. Ann Rheum Dis. 2008. PMID: 18276741 Clinical Trial.
-
The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.Autoimmun Rev. 2010 Jul;9(9):609-14. doi: 10.1016/j.autrev.2010.05.007. Epub 2010 May 7. Autoimmun Rev. 2010. PMID: 20452466 Review.
-
Rituximab in primary Sjögren's syndrome: a ten-year journey.Lupus. 2014 Nov;23(13):1337-49. doi: 10.1177/0961203314546023. Epub 2014 Aug 5. Lupus. 2014. PMID: 25096066 Review.
Cited by
-
Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology.Front Pharmacol. 2024 May 17;15:1377055. doi: 10.3389/fphar.2024.1377055. eCollection 2024. Front Pharmacol. 2024. PMID: 38828450 Free PMC article. Review.
-
Investigative biological therapies for primary Sjögren's syndrome.Arch Med Sci. 2020 Jul 15;20(2):506-516. doi: 10.5114/aoms.2020.97288. eCollection 2024. Arch Med Sci. 2020. PMID: 38757038 Free PMC article.
-
Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy.J Transl Autoimmun. 2024 Mar 3;8:100238. doi: 10.1016/j.jtauto.2024.100238. eCollection 2024 Jun. J Transl Autoimmun. 2024. PMID: 38496268 Free PMC article.
-
Current developments and opportunities of pluripotent stem cells-based therapies for salivary gland hypofunction.Front Cell Dev Biol. 2024 Jan 19;12:1346996. doi: 10.3389/fcell.2024.1346996. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38313227 Free PMC article. Review.
-
Estimated prevalence, incidence and healthcare costs of Sjögren's syndrome in France: a national claims-based study.RMD Open. 2024 Feb 2;10(1):e003591. doi: 10.1136/rmdopen-2023-003591. RMD Open. 2024. PMID: 38307699 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical